A CME/CE Educational Pamphlet

Release Date: July 6, 2010
Expiration Date: July 6, 2011

A recent multinational survey based on acute care hospital chart reviews utilized American College of Chest Physicians (ACCP) guidelines to assess the risk of developing venous thromboembolism (VTE). Survey results showed that less than half of at-risk medical patients received ACCP-recommended VTE prophylaxis, highlighting the important need for proactive identification of at-risk medical patients in acute care through stratification and institution of guideline-recommended preventive measures. In addition to inconsistent recognition and underutilization of appropriate preventive strategies, there are also important clinical needs concerning the treatment of VTE. For instance, the transition from the hospital environment to the home or other outpatient setting is a time when suboptimal management or gaps in communication can adversely impact outcomes. Recognizing these clinical gaps in patient care, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has established prophylaxis and treatment of VTE as a safety priority in their currently published National Patient Safety Goals (NPSGs).

This Educational Pamphlet will address methods to assess risk for deep-vein thrombosis (DVT), duration of VTE prophylaxis and treatment, and other important issues relevant to the contemporary treatment of VTE.

Agenda
Front Matter:	5 minutes
Pamphlet Presentation:	45 minutes
Evaluation Forms:	5 minutes
Posttest:	5 minutes
Total Estimated Time to Complete This Activity:	1 hour

This activity is intended for hospitalists, orthopedic surgeons, hematologists, intensivists, general internal medicine and family physicians, and nurses who treat patients with or at risk for DVT.

PHYSICIANS
SCEPTER designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity, VTE Prevention and Treatment: A Practical ‘How To”, has been reviewed and is acceptable for up to 1 Prescribed
credit(s) by the American Academy of Family Physicians. AAFP accreditation begins July 6, 2010. Terms of approval is for one year(s) from this date, with option for yearly renewal.

NURSES
This educational activity for 1.0 contact hour is provided by Global Education Group. For information about the nursing accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

SCEPTER is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Global Education Group is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been reviewed for relevance, accuracy of content, and fair balance by CME Peer Review, LLC.

There is no fee to participate in this activity.

Participants should read the educational objectives, review the pamphlet in its entirety, and complete the posttest and evaluation.

This activity has been prepared under the direction of Stephan Moll, MD Associate Professor Division of Hematology-Oncology Department of Medicine University of North Carolina School of Medicine Chapel Hill, North Carolina AAFP Reviewer Michael E. Cobble, MD, AAFP, FNLA Director, Canyons Medical Center Sandy, Utah Adjunct Faculty, University of Utah School of Medicine Salt Lake City, Utah Chief Medical Officer, Atherotech, Inc. Birmingham, Alabama

Policy on Disclosure
SCEPTER and Quintiles Medical Education adhere to the ACCME Essential Areas and Policies, including the Standards for Commercial Support, regarding industry support of CME. Disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, will be disclosed to learners.

Global Education Group Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Amanda Glazer, PhD, Jackie Dawson, MSN, and Michael Perlmutter, MS, PharmD, have no significant financial relationships to disclose.

Faculty Disclosure
Stephan Moll, MD, has received honoraria from Ortho-McNeil and International Technidyne Corporation. He has received research support from International Technidyne Corporation. Dr. Moll may discuss unlabeled/unapproved uses of dabigatran and rivaroxaban.

AAFP Reviewer Disclosure
Michael Cobble, MD, has served on the speakers bureaus for Abbott, AstraZeneca, Eli Lilly, GlaxoSmithKline, Forest and Novo Nordisk. He has served as a consultant for Atherotech, Inc.

CME Peer Review, LLC, Conflict of Interest Resolution Statement
Reviewers are required to disclose all relevant relationships with any commercial interest to CME Peer Review, LLC, prior to being accepted as a reviewer. Reviewers are required to update such information, are vetted and are determined to be free of conflict of interest prior to conducting each activity content evaluation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and SCEPTER do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor, the educational partner, or the supporter. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

To review SCEPTER’s privacy policy, Click Here

• Adobe Reader 9® for viewing PDF files (for downloadable version of Pamphlet)